- April 2026: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and other peptides left the FDA's Category 2 ("may present significant safety risks") list because the original nominators withdrew their nominations. The FDA Category 2 page now lists them under "nominated but withdrawn".
- 23-24 July 2026: the FDA Pharmacy Compounding Advisory Committee (PCAC) reviewed seven peptides for the US 503A Bulks List. FDA staff proposed that none be included; the committee voted in favour of six and against one (Emideltide/DSIP).
- Reported tallies: BPC-157, KPV and TB-500 each 8 yes, 6 no, 1 abstain; MOTS-c 7-5-2; Semax 8-5-1; Epitalon 7-4-1; Emideltide rejected 6-7-1 (secondary reporting; FDA has not posted minutes we could find).
- The votes are advice only. As of late September 2026 no proposed rule adding these peptides to the 503A Bulks List has been published, and none of them is an FDA-approved drug.
- Nothing in this changes EU law: US compounding lists do not apply in the EU, and none of these peptides is an authorised medicine here.
2026 has been the most active year for research-peptide regulation in the United States in a decade. In two steps, the FDA moved a group of widely studied peptides out of its compounding "safety risk" category and put seven of them in front of an advisory committee. The committee sided with the peptides, against the recommendation of FDA's own reviewers. Below is what we could confirm on primary FDA pages, what comes from secondary reporting, and what it means for laboratories in Europe.
Step 1: Category 2 removal (April 2026)
Under its interim compounding policy, the FDA sorts nominated bulk substances into categories. Category 2 holds substances the agency believes "may present significant safety risks", which in practice meant pharmacies faced enforcement if they compounded them. BPC-157 and several other popular peptides had been in Category 2 since 2023.
On 15 April 2026, according to law-firm summaries of the announcement, the FDA gave notice that 12 peptides would leave Category 2 after seven days because their nominators had withdrawn the nominations. The FDA's Category 2 page (last updated 22 April 2026) confirms the result: BPC-157, TB-500 (thymosin beta-4 fragment), KPV, MOTS-c, Semax, Epitalon, GHK-Cu, Melanotan II, Emideltide (DSIP), cathelicidin LL-37, Dihexa and PEG-MGF now appear only under "bulk drug substances nominated but withdrawn".
Removal from Category 2 is not the same as permission. The peptides were not moved to Category 1 or onto the 503A Bulks List; they simply lost the safety-risk label that justified enforcement, leaving them in a regulatory grey zone until the FDA decides.
Step 2: the PCAC meeting (23-24 July 2026)
A Federal Register notice published on 16 April 2026 (Docket FDA-2025-N-6895) announced a two-day PCAC meeting at FDA's White Oak campus to discuss whether seven peptide substances, each in free-base and acetate form, should be added to the 503A Bulks List. That list is what allows US state-licensed pharmacies to compound a drug from a bulk substance that has no USP monograph and is not part of an approved drug.
| Peptide | Use FDA reviewed | FDA staff proposal | Committee vote (reported) |
|---|---|---|---|
| BPC-157 | Ulcerative colitis | Do not include | 8 yes, 6 no, 1 abstain |
| KPV | Wound healing, inflammatory conditions | Do not include | 8 yes, 6 no, 1 abstain |
| TB-500 | Wound healing | Do not include | 8 yes, 6 no, 1 abstain |
| MOTS-c | Obesity, osteoporosis | Do not include | 7 yes, 5 no, 2 abstain |
| Emideltide (DSIP) | Opioid withdrawal, insomnia, narcolepsy | Do not include | 6 yes, 7 no, 1 abstain |
| Epitalon | Insomnia | Do not include | 7 yes, 4 no, 1 abstain |
| Semax | Cerebral ischemia, migraine, trigeminal neuralgia | Do not include | 8 yes, 5 no, 1 abstain |
Two details from the FDA briefing document stand out. First, every nomination on the agenda had been withdrawn by its nominator (Wells Pharmacy Network and LDT Health Solutions on behalf of the International Peptide Society), yet the FDA chose to bring the substances to the committee anyway. Second, for all 14 questions the FDA proposed that the substance NOT be included. Press coverage summarised the reviewers' concern as human studies that were short, small and insufficient to establish safety or effectiveness for the uses under review.
The committee disagreed on six of seven. The margins were narrow, and STAT reported that most members voting yes had ties to the peptide industry. The roster shows the panel included several integrative-medicine physicians alongside pharmacy representatives.
What happens next in the US
- The FDA is not bound by the vote. It must decide whether to accept each recommendation.
- Adding a substance to the 503A Bulks List requires notice-and-comment rulemaking: a proposed rule, a comment period, then a final rule. Law firms estimate this takes months to years.
- As of late September 2026 we found no proposed rule in the Federal Register, and the 503A Bulks List does not yet include any of the six peptides.
- The remaining Category 2 removals (for example GHK-Cu, LL-37, Melanotan II) are, per law-firm reports, expected at a further PCAC meeting before February 2027.
- Even a final listing would cover compounding by US pharmacies for individual prescriptions. It would not make any of these peptides an FDA-approved drug.
What it means (and does not mean) for EU researchers
The short answer: the US decisions are an important signal about scientific and political attention, but they change nothing in EU law. FDA categories and the 503A Bulks List are US mechanisms under the Federal Food, Drug, and Cosmetic Act and have no legal effect in Lithuania or any other EU member state.
- No EU authorisation: none of BPC-157, TB-500, KPV, MOTS-c, Semax or Epitalon holds an EU marketing authorisation from the EMA or the European Commission. Semax has national registration history in Russia, not in the EU.
- Different compounding rules: in the EU, pharmacy-prepared (magistral and officinal) medicines are excluded from Directive 2001/83/EC and regulated nationally. There is no EU equivalent of the 503A Bulks List to be "added" to.
- Sport: WADA still prohibits BPC-157 (S0, non-approved substances) and TB-500 (S2). A US compounding decision does not change the WADA list.
- Research supply is unaffected: laboratory research material is characterised by identity, purity and batch documentation, not by any therapeutic status. What matters for a research lab is still HPLC purity, LC-MS identity and a batch COA.
For scientists the more useful takeaway is the FDA briefing material itself. It is a public, structured review of the published evidence on each peptide, including gaps in human data, and it is worth reading before designing a study. It also shows where regulators want better data: longer and larger controlled studies, and clearer characterisation of the substance, including impurities and salt form (free base versus acetate).
Regulatory news for information only, not legal or medical advice. Cryopept Labs products are for laboratory research use only.
